SHANGHAI KAIBAO(SZ:300039)2014-04-08 16:00Financial Performance - Total revenue for Q1 2014 was CNY 379,967,646.73, an increase of 14.46% compared to CNY 331,970,254.99 in the same period last year[8]. - Net profit attributable to ordinary shareholders was CNY 79,965,763.91, reflecting a growth of 16.99% from CNY 68,354,357.10 year-on-year[8]. - Basic earnings per share increased by 15.38% to CNY 0.15, compared to CNY 0.13 in the same period last year[8]. - The company reported a total comprehensive income of CNY 79,965,763.91 for Q1 2014, compared to CNY 68,354,357.10 in Q1 2013[55]. - Total operating revenue for Q1 2014 was CNY 379,967,646.73, an increase of 14.4% compared to CNY 331,970,254.99 in Q1 2013[54]. - Net profit for Q1 2014 reached CNY 79,965,763.91, representing a 16.9% increase from CNY 68,354,357.10 in Q1 2013[55]. - Cash flow from operating activities for Q1 2014 was CNY 78,829,789.54, down 19.5% from CNY 97,960,083.72 in Q1 2013[57]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,879,796,345.32, a rise of 6.15% from CNY 1,770,810,467.77 at the end of the previous year[8]. - The company reported a total current liability of CNY 171,952,875.17, an increase from CNY 142,202,340.82, indicating a rise of approximately 20.9%[51]. - The company's retained earnings increased to CNY 519,848,110.78 from CNY 439,882,346.87, showing a growth of about 18.2%[51]. - The company's cash and cash equivalents decreased slightly to CNY 813,440,639.82 from CNY 814,013,341.73, indicating a marginal decline of 0.07%[49]. - Accounts receivable increased to CNY 311,668,778.20 from CNY 267,338,264.78, representing a growth of about 16.6%[49]. Research and Development - The company aims to diversify its product offerings beyond its main product, Tanreqing Injection, by enhancing R&D capabilities and seeking new product introductions and acquisition opportunities[11]. - The company is conducting III phase clinical research for "Hua Dan An Shen He Ji," which targets a large market with a wide clinical application[24]. - The company applied for four invention patents related to its main product, "Tan Re Qing Injection," which could enhance its competitive advantage if approved[24]. - The company is conducting Phase III clinical trials for the "Phlegm-Heat Clearing Oral Solution" as of March 31, 2014, optimizing product structure[28]. - The company has established a clinical pharmacokinetics research plan for the "Phlegm-Heat Clearing Injection" and is planning to conduct human pharmacokinetics studies[28]. Investment and Fundraising - Total fundraising amount reached CNY 973.76 million, with CNY 13.60 million invested in the current quarter[35]. - Cumulative investment of CNY 586.91 million from fundraising, with a 0% change in usage of funds[35]. - The modernization of traditional Chinese medicine project has achieved 99.74% of its planned investment, totaling CNY 24.99 million[35]. - CNY 600 million has been permanently supplemented to working capital as of March 31, 2014[36]. - The company plans to continue using excess fundraising for operational needs, with CNY 80 million allocated for daily production[36]. Market and Competitive Position - The company has received recognition for "Tan Re Qing Injection" being included in national treatment guidelines for H7N9 avian influenza[26]. - The company has not encountered any significant changes in project feasibility or investment progress[36]. - The company has committed to not changing the purpose of the fundraising during the control period[33]. - The company is collaborating with universities for research on alternative medicines, contributing to the sustainable use of endangered medicinal materials[39]. - The company has made significant progress in the development of new products and technologies, enhancing its core competitiveness[28].